9H-fluoren-9-ylmethyl 2-[[(2S)-4-hydroxy-3-oxobutan-2-yl]amino]acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 9H-fluoren-9-ylmethyl 2-[[(2S)-4-hydroxy-3-oxobutan-2-yl]amino]acetate
• 化学式: C₂₀H₂₁NO₄
• 分子量: 339.4
• InChiKey: XXWUAFMSPXXZON-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• SPIROIMIDAZOLONE DERIVATIVE
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2433940A1

  公开（公告）日：2012-03-28

  The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

  本发明涉及下式（1）所代表的化合物： 其中 W、X、Y、R1、R2、R33、R34、m 和 n 如权利要求中定义，或其药理上可接受的盐。
• PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME
  申请人：AMYLIN PHARMACEUTICALS, LLC

  公开号：US20140371148A1

  公开（公告）日：2014-12-18

  Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.
• [EN] SPIROIMIDAZOLONE DERIVATIVE<br/>[FR] DÉRIVÉ DE SPIROIMIDAZOLONE
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2010126030A1

  公开（公告）日：2010-11-04

  本発明は、下記式(１)で表される化合物またはその薬理学的に許容される塩である; (式中、Ｗ、Ｘ、Ｙ、Ｒ１、Ｒ２、Ｒ３３、Ｒ３４、ｍ、ｎは請求の範囲に記載のそれと同意義である。)。
• [EN] MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES MACROCYCLIQUES À LARGE SPECTRE
  申请人：RQX PHARMACEUTICALS INC

  公开号：WO2014081886A1

  公开（公告）日：2014-05-30

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type (1) signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.